Equity research is something we think we're good at...
We conduct equity research on Life Sciences companies that are publicly traded on the Australian Securities Exchange. This is a large and growing sector of Australia's equity market, with in excess of 90 companies represented. Equity research is something we think we are good at, and the Life Sciences sector is something we're passionate about.
For our client companies we will publish one detailed research note each year as well as four update notes. These notes will be distributed through channels proprietary to our network of investors who specialise in Life Sciences.
The Declaration of Independence by John Trumbull, commissioned 1817
Yes. Unequivocally so. When it comes down to it, the best way for equity research to be independent is for analysts to have an independent character. The kind of guy (or girl) who would call CSL Ltd (ASX: CSL) a buy in 2003 when everyone hated it and long before that Melbourne-based plasma products supplier turned into the world's 30th largest pharma company.
A lot of people suspect that the main reason brokers maintain Research Departments these days is to try and capture fees from the Corporate work down the track. Is 'paid for' research more independent than that? Well, there are two ways we think we will be independent. Firstly, our client companies will pay up-front so that there can be no possibility of a research finding being swayed through the threat of withheld payments. Secondly, our client companies will sign a Memorandum of Understanding with us prior to coming on board affirming that once the research process is underway they will not seek to coerce our analysts into changing their price target, earnings numbers, or opinions expressed in the reports.